Safety and Efficacy of Inebilizumab in AQP4+ NMOSD Participants with History of Immunosuppression Treatment Prior to N-MOmentum Study (P13-5.003)

作者
Friedemann Paul,Roman Marignier,John William Lindsey,Ho Jin Kim,Dewei She,Daniel M. Cimbora,Kristina R. Patterson,Bruce Cree
出处
期刊:Neurology [Lippincott Williams & Wilkins]
卷期号:100 (17_supplement_2)
标识
DOI:10.1212/wnl.0000000000202412
摘要

Objective: To evaluate long-term outcomes of inebilizumab treatment in AQP4+ NMOSD participants from the N-MOmentum trial with a history of immunosuppressant therapy as compared to those without. Background: Inebilizumab (anti-CD19 B-cell-depleting antibody) is approved for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adults seropositive for aquaporin-4 antibody (AQP4+). Immunosuppressants were prohibited during the N-MOmentum pivotal trial, although many participants had a history of immunosuppressant therapy before enrolment. Design/Methods: N-Momentum (NCT02200770) was a 28-week-randomized-phase-2/3 trial of inebilizumab vs placebo, with an optional Open-Label-Extension (OLE) (>2 years). Immunosuppressant medication for the prevention or treatment of NMOSD relapses was allowed prior to dosing on Day 1. In this analysis, AQP4+ participants who received inebilizumab (through OLE) were grouped by no history of immunosuppression therapy beyond treatment of acute NMOSD attacks (naïve), or prior azathioprine (AZA) and/or mycophenolate mofetil (MMF) therapy. Outcomes included annualized relapse and hospitalization rates, as well as safety assessments. Results: Among inebilizumab participants, 94 received prior-AZA/MMF and 103 were immunosuppressant-naïve. The total patient-years of inebilizumab treatment in the prior-AZA/MMF group was 300.35 and for immunosuppressant-naïve participants, 335.7. The annualized relapse rate (95% confidence interval [CI]) for participants with prior-AZA/MMF was 0.11 (0.07, 0.17), compared to 0.08 (0.05, 0.14) for naïve. The annualized NMOSD-related inpatient hospitalization rate (annualized rate [95% CI]) for prior-AZA/MMF was 0.15 (0.08, 0.27), and 0.12 (0.06, 0.22) for naïve. The percentage of participants with ≥1 study drug-related-treatment-emergent-adverse-event (TEAE) was 30.9% (29/94) in prior-AZA/MMF and 46.6% (49/103) of naïve; 4.3% (4) of prior-AZA/MMF and 5.8% (6) of immunosuppressant-naïve reported ≥1 study drug-related-serious-adverse-event. Most adverse events were infection-related for both groups; (72.3% (68/94) for prior-AZA/MMF and 76.7% (79/94) for naïve). Conclusions: This post hoc analysis evaluating long-term outcomes of inebilizumab in AQP4+ NMOSD participants treated with prior AZA/MMF therapy demonstrated a similar efficacy and safety profile as participants without prior immunosuppressant therapy. Disclosure: The institution of Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mitsubishi Tanabe PC (MTPC). The institution of Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aarhus University. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Paul has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi Genzyme. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CELGENE. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Bayer. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Novartis. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for ACRELION. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Viela Bio. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pfizter. Dr. Paul has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck Serono. The institution of Dr. Paul has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Springer. Dr. Marignier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Marignier has received personal compensation in the range of $0-$499 for serving as a Consultant for ALEXION. Dr. Marignier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ROCHE. Dr. Marignier has received personal compensation in the range of $500-$4,999 for serving as a Consultant for HORIZON THERAPEUTICS. Dr. Marignier has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for ROCHE. Dr. Lindsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Genentech. Dr. Lindsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Banner Life Sciences. Dr. Lindsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Lindsey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mapi. Dr. Lindsey has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Teva. The institution of Dr. Lindsey has received research support from Genentech. Dr. Kim has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Aprilbio, HanAll BioPharma, Viela Bio. Dr. Kim has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Alexion, Biogen, Celltrion, Eisai, Merck Serono, Novartis, Sanofi Genzyme, Teva-Handok. Dr. Kim has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Multiple Sclerosis Journal, Journal of Clinical Neurology. Dewei She has received personal compensation for serving as an employee of Horizon Therapeutics. Dr. Cimbora has received personal compensation for serving as an employee of Viela Bio. Dr. Cimbora has received stock or an ownership interest from Viela Bio. Dr. Patterson has received personal compensation for serving as an employee of Hospital of the University of Pennsylvania. Dr. Patterson has stock in Horizon Therapeutics. The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Atara. The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Autobahn. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avotres. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gossamer Bio. Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neuron23. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Pharma. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal/Sandoz. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Therini. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. The institution of Dr. Cree has received research support from Genentech. Dr. Cree has received publishing royalties from a publication relating to health care.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
初景发布了新的文献求助10
1秒前
今后的应助被斯多姆采纳,获得10
1秒前
1秒前
Eternity完成签到,获得积分10
1秒前
天天快乐的应助被Jase采纳,获得10
2秒前
津津完成签到,获得积分10
2秒前
yosh发布了新的文献求助10
2秒前
十一完成签到 ,获得积分10
2秒前
jie发布了新的文献求助10
3秒前
莓莓发布了新的文献求助10
3秒前
冰棍发布了新的文献求助10
3秒前
苁蓉远志完成签到 ,获得积分10
3秒前
molihuakai的应助被白春蕾采纳,获得10
4秒前
4秒前
MIN完成签到,获得积分10
5秒前
狮子发布了新的文献求助10
5秒前
NOIR4LU完成签到 ,获得积分10
5秒前
一谷完成签到 ,获得积分10
5秒前
白XX发布了新的文献求助10
6秒前
xyt完成签到 ,获得积分10
6秒前
7秒前
molihuakai的应助被想人陪的蚂蚁采纳,获得10
7秒前
Lu丶L完成签到,获得积分10
7秒前
8秒前
8秒前
KMS完成签到,获得积分10
9秒前
moon发布了新的文献求助10
9秒前
9秒前
白芷完成签到,获得积分10
9秒前
Luna完成签到 ,获得积分10
11秒前
晓天发布了新的文献求助10
11秒前
11秒前
Jasper的应助被璐璐采纳,获得10
11秒前
桐桐的应助被冰棍采纳,获得10
11秒前
桐桐的应助被冰棍采纳,获得10
12秒前
JamesPei的应助被姜OMG采纳,获得10
12秒前
琪琪完成签到 ,获得积分10
12秒前
小波儿发布了新的文献求助10
12秒前
唐唐发布了新的文献求助10
12秒前
13秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527